A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)

A randomized, multicenter, open-label, active-controlled Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of multiple intravaginal doses of GenSci142 in patients with bacterial vaginosis (BV).

NCT Number	NCT07663838
Lead Sponsor	Changchun GeneScience Pharmaceutical Co., Ltd.
Conditions	Randomized, Open-label, Safety, Tolerability, Pharmacokinetics, Bacterial Vaginosis
Enrollment	30 participants
Start Date	2026-06-15
Primary Completion	2027-01-05 (estimated)
Study Completion	2027-05-05 (estimated)
Updated on ClinicalTrials.gov	2026-06-23